Alnylam Pharmaceuticals, Inc. (ALNY) Stock: Price, Forecast & Analyst Target
Alnylam Pharmaceuticals, Inc. (ALNY) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $147.82 (-1.06%), as of the Nov 19, 2026 trading session; market cap $19.8B.
Educational signal · not a buy or sell recommendation · How to read this
Alnylam Pharmaceuticals, Inc. · ALNY · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Alnylam is a commercial biopharmaceutical company built around RNA interference: approved rare-disease medicines support an expanding development engine, while alliances extend the platform into additional organs and diseases. Its appeal now depends on whether commercial growth can keep supporting profit and cash generation as research and commercialization costs remain substantial.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Alnylam Pharmaceuticals (ALNY)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, but a full valuation. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Slipping.
- quarterly revenue $1.29B (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 5 of the last 8 reports
- Altman Z 3.72 · Piotroski F 5
Holding back: weak price trend
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 73 | Strong | |
| 63 | Fair | |
| 74 | Strong | |
| 74 | Strong | |
| 72 | Strong | |
| 72 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $147.82 | |
| Change on the day | -1.06% | |
| 52-week range | $147.82–$479.79 | |
| Market capitalisation | $19.8B | — |
| Price / earnings (trailing) | 7.68 | |
| Shares traded on the day | 2.15M | |
| Beta (volatility vs the S&P 500) | 0.27 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Alnylam Pharmaceuticals (ALNY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Alnylam Pharmaceuticals (ALNY), and what does it report?
Short answer · as of
Alnylam discovers, develops, and commercializes medicines that use RNA interference to silence disease-causing targets.
Research dated 2026-09-12.
Demand comes from prescribing and patient access for approved therapies such as GIVLAARI, ONPATTRO, and OXLUMO; pipeline progress and partnerships broaden the business beyond those brands.
This is not merely a research platform awaiting commercialization. Consolidated results reflect a commercial drug business alongside heavy internal development and alliance activity, while the named segment view highlights GIVLAARI and ONPATTRO without serving as a complete map of revenue.
What do the latest results show for Alnylam Pharmaceuticals (ALNY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.29B.
Research dated 2026-09-12.
Revenue and gross profit advanced from the preceding period, but operating profit, net income, and diluted earnings per share retreated as research and selling and administrative costs climbed. The latest release also landed below revenue and earnings expectations, making cost absorption—not merely top-line growth—the immediate operating test.
Management has attached a longer-duration catalyst to nucresiran in hATTR polyneuropathy, with any launch conditional on favorable late-stage results and regulatory approval. That is an ambition with explicit gates, not evidence that commercial contribution has begun.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.29B | $164M | $1.20 (diluted) |
| Q1 FY2026 | $1.17B | $206M | $1.51 (diluted) |
| Q4 FY2025 | $1.10B | $186M | $1.37 (diluted) |
| Q3 FY2025 | $1.25B | $251M | $1.84 (diluted) |
What are the financial strengths and risks for Alnylam Pharmaceuticals (ALNY)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and short-term investments exceed total debt by a wide margin, have risen across recent reporting points, and sit alongside positive operating cash flow in the latest periods. This gives Alnylam meaningful capacity to fund research and commercialization while maintaining net cash.
Risk now sits less in immediate financing pressure than in execution against a large cost base. Research and selling expenses remain substantial and increased in the latest period; if commercial growth weakens or a major program stalls, operating profit and cash generation can compress quickly. Valuation ratios also place considerable weight on continued earnings delivery, despite uneven results relative to expectations.
What should you watch next at Alnylam Pharmaceuticals (ALNY)?
Short answer · as of
Current published price targets run low $225.00 · high $455.00 · consensus $331.93 · median $322.00 against a quoted price of $147.82 (as of Nov 19, 2026).
Research dated 2026-09-12.
At the next release, compare revenue growth with published expectations, then trace how much reaches gross profit after research and commercialization spending. Operating cash flow, capital spending, and the cash balance will show whether accounting profitability is translating into additional funding capacity.
Beyond the financial statements, nucresiran’s late-stage result and regulatory path are the concrete gates behind management’s launch timetable. Longer-range analyst estimates assume sustained expansion but span a broad range, so any narrowing would signal greater confidence in commercial scaling.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Alnylam Pharmaceuticals compare with its peers?
Short answer
Alnylam Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Alnylam belongs between commercial specialty biopharma and platform biotechnology. Unlike a development-only biotech, it has approved RNAi medicines, positive recent earnings, operating cash generation, and net cash; unlike a conventional drug portfolio, its identity and pipeline remain concentrated around a shared gene-silencing technology and amplified through external alliances.
The practical comparison is therefore broader than pipeline breadth or current sales. Relevant distinctions include the durability of branded demand, the productivity of continuing research spending, and the balance between internal programs and alliances.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $341.25 Nov 19, 2026 | $65.1B | 86 5-pillar Nov 18, 2026 | |
| $273.09 Nov 19, 2026 | $72.0B | 78 5-pillar Nov 18, 2026 | |
| Alnylam Pharmaceuticals (ALNY) — this page | $147.82 | $19.8B | 72 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $225.00 – $455.00
- Consensus target
- $331.93
- Median target
- $322.00
Consensus record · Captured .
Measured against a quoted price of $147.82 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 14
- Identified insiders
- 6
- Purchases
- 2
- Sales
- 6
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ALNY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ALNY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Alnylam Pharmaceuticals (ALNY)?
Common Questions About ALNY (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Alnylam make money from RNA interference?
The operating model combines sales of approved therapies with partnered development and commercialization. The named segment view includes GIVLAARI and ONPATTRO, while consolidated revenue is materially broader than those disclosed lines.
Why did Alnylam’s profit fall while revenue rose in the latest period?
Research and selling and administrative costs increased enough to outweigh the rise in gross profit. Revenue still expanded, but less of that growth reached operating profit and net income.
Can Alnylam fund its RNAi pipeline without leaning on new debt?
The current balance sheet holds net cash, and recent operating cash flow has been positive, indicating substantial internal funding capacity. That cushion still depends on commercial cash generation keeping pace with research and commercialization spending.
What must happen before Alnylam can launch nucresiran for hATTR polyneuropathy?
Management’s timetable depends on favorable late-stage clinical results and regulatory approval. Until those gates are cleared, nucresiran remains a development program rather than a commercial contributor.
What is the ALNY stock price today?
The last price recorded for Alnylam Pharmaceuticals, Inc. (ALNY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ALNY price target?
The analyst consensus price target for Alnylam Pharmaceuticals, Inc. (ALNY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ALNY
Funds in our ETF coverage that list ALNY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| NestYield Dynamic Income ETF (EGGY) | 4.66% | |
| Nuveen ESG Mid-Cap Growth (NUMG) | 3.52% | |
| FIDELITY WOMENS LEADERSHIP ETF (FDWM) | 1.60% |